Baseline and 6-Week Follow-Up Levels of PAF and Activity of Its Metabolic Enzymes in Patients With Heart Failure and Healthy Volunteers—A Pilot Study

Abstract

This study aimed at evaluating the changes in platelet-activating factor (PAF) and its metabolic enzymes over a 6-week follow-up period in patients with newly diagnosed heart failure ([HF] n = 12) compared with age-, sex-, and BMI-matched apparently healthy volunteers (n = 10). The PAF, its key biosynthetic enzymes (lyso-PAF acetyltransferase [lyso-PAF-AT] and dithiothreitol [DTT]-insensitive CDP choline: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase [PAF-CPT]), and its catabolic isoenzymes (PAF-acetylhydrolase [PAF-AH] and lipoprotein-associated phospholipase A2 [Lp-PLA2]) were measured in serum and leukocytes of participants. At baseline, patients with HF had lower median activities of lyso-PAF-AT ( P < .001) and PAF-CPT ( P = .07) in parallel with PAF levels ( P = .05) and higher activities of PAF-AH ( P = .02) and Lp-PLA2 ( P < .001) than controls. At follow-up, PAF-CPT and PAF levels marginally increased ( P = .1), lyso-PAF-AT ( P < .001) remained downregulated, while PAF-AH ( P = .004) and Lp-PLA2 ( P < .001) remained elevated compared with the controls. Newly diagnosed patients with HF under drug treatment have an affected profile of PAF biosynthetic enzymes and especially lyso-PAF-AT.